Sudden unexpected death (SUD) has been associated with low or undetectable concentrations of antiepileptic drugs in patients with epilepsy suggesting that a sudden fall in plasma levels of these drugs might be a critical factor for the occurrence of SUD. We studied the changes in arrhythmia profile and heart-rate variability, during abrupt withdrawal of carbamazepine and phenytoin treatment in 10 patients with side effects on these drugs. Continuous ECG recording and daily measurements of drug plasma concentrations were performed from the last day of steady-state treatment and the following 4 days. Three patients had a IO-fold increase in ventricular premature beats. In addition, there was a significant reduction in heart-rate variability, assessed over 24 hours, in both the time (SDNN index, P = 0.03) and frequency domains from days 1-5. In the frequency domain analysis there was a significant reduction in total power (P = 0.01). very-low-frequency power (P = 0.004) and in low-frequency (LF) power (P = 0.01). Similar reductions in heart-r&e variability and increases in ventricular automaticity have been associated with increased mortality in other patient groups. Two factors that might contribute to the increased rate of SUD in patients with epilepsy have thus been identified.
INTRODUCTION
Sudden unexpected, unexplained death (SUD) is more common in patients with epilepsy compared with the general population I**. The mechanism for SW in epilepsy is unclear, but there are several theories such as: cardiac tachy-or bradyarrhythmias related to paroxysmal autonomic dysfunction; respiratory arrest3 and neurogenic pulmonary oedema4; events occurring in connection with overt or subclinical seizures. Low or undetectable post-mortem blood concentrations of antiepileptic drugs has been a frequent finding in cases of SW (reviewed in $6). The relevance of these findings has been questioned on methodological grounds, but they have raised a question as to the role of sudden drug withdrawal or non-compliance as precipitating factors for SW.
The antiepileptic drugs carbamazepine and phenytoin are sodium-channel blockers with a membranestabilizing effect in the central nervous system7 as well as in the cardiac conduction system and myocardium . 8-1o Carbamazepine may induce cardiac bradyarrhythmias, which has caused safety concerns' I* '* and phenytoin has been used and classified as an antiarrhythmic drug". A sudden withdrawal of such cardioactive drugs might theoretically induce both direct and indirect cardiac changes of relevance for SW unrelated to seizure activity. We therefore conducted a prospective study to assess the changes of the arrhythmia profile and the activity of the autonomic nervous system, as reflected by changes in heart-rate variability in connection with abrupt withdrawal of carbamazepine or phenytoin treatment.
PATIENTS AND METHODS

Study population
Ten patients (6 men) with a mean age of 66 (SD& 10) years were included. All were under long-term treatment with carbamazepine or phenytoin, and in all an 370 G. Kennebiick et al abrupt withdrawal of the antiepileptic drugs was justified on clinical grounds. Nine had suspected side effects of carbamazepine (n = 7) or phenytoin (n = 2). The reason for withdrawal was extracardiac adverse effects in two patients (pts 1, 2). In three patients (pts 4, 9, 10) the type of cerebral symptoms and electrocardiography (ECG) suggested bradycardiarelated symptoms that might have been provoked or exaggerated by the drugs. Three patients (pts 5, 7, 8) had asymptomatic bradycardias recognized in connection with a 24-hour ECG prevalence study of arrhythmias in a population of patients with epileptic seizures with a normal standard 12-lead surface ECG and without symptoms suggestive of arrhythmias". Patient 3 was initially suspected to have a tachycardia bradycardia syndrome, but was found to have paroxysmal atria1 flutter without bradycardia. The remaining patient (pt 6) had trigeminal neuralgia and was on carbamazepine, which was ineffective and motivated a change in therapy.
Except for well-regulated mild hypertension in two patients and a clinically compensated congestive heart failure in one patient, there was no evidence of cardiovascular or clinically significant structural heart disease, Table 1 .
All patients were hospitalized for safety reasons, and after this study further medical investigations or treatment were started. During the 5-day study period, all patients carried a two-channel ECG cassette recorder (Medilog II, Oxford Medical Systems). An electrode position similar to VI and V6 in a 1Zlead ECG was used for assessment. The recording quality was checked with regard to stability and ability to detect P-waves. All medication was unchanged during the first 24 hours. The antiepileptic drug was then withdrawn and plasma concentrations of the drugs were followed daily. Plasma levels of carbamazepine and phenytoin were determined using a slight modification of the high-performance liquid chromatography previously described 13. All tapes were analysed as follows.
Arrhythmias. The tapes were first automatically screened for the following arrhythmias: sinus pauses 2 1.5 seconds, second-and third-degree atrioventricular block, ventricular premature beats and ventricular tachycardias as well as supraventricular tachyarrhythmias. The results were then manually checked in two steps, first by a skilled nurse for determination of the correct classification of tachy-and bradyarrhythmias as well as for premature beats. In addition, one of the cardiologists reviewed the classification of all arrhythmias.
The following definitions were used. A sinus pause was an RR interval 1 1.5 seconds, excluding (1) compensatory pauses following premature QRS complexes, (2) posttachycardia pauses, i.e. a pause preceded by a brief increase in heart rate and followed by a gradual return in heart rate to the pre-pause level, and (3) pauses due to a blocked premature P-wave.
Conduction
intervals.
All recordings were printed onto paper with a speed of 50 mm/second, blind coded, and the measurements were then made by a person, who could identify each individual, for the purpose of performing all measurements in the same channel, but who was unaware of the order of the five recordings. All five recordings were analysed at the same time for each individual, in order to have the same definition of all measured points. The conduction intervals were measured during the same time period every day. A stable recording period was chosen between 5.30 and 6.30 pm. All measurements were performed on a digitizer table (Kurta IS/ADB, Kurta Corporation, USA) working in point mode with a resolution of f0.002 mm. The measured intervals were: the PP, RR, PQ, QRS and QT intervals, which were calculated as the mean of three intervals. The JT interval was obtained by subtracting the QRS from the QT interval. The JT and QT intervals were also heartrate corrected according to the method by Bazett (QTc = QT/m in seconds and JTc = JT/m in seconds)14. The mean RR interval (the inverse of the mean heart rate) of 24 hours was calculated in the following way: the mean RR interval of every 500-beat segment was determined and then a mean of all segments over 24 hours was calculated.
Heart-rate variability. This was analysed in the time and frequency domains. The RR-intervaIs and their corresponding classifications of QRS complexes were exported as an ASCII text file from the commercially available ECG-analyser in the Aspect Holter System (Daltek Biomedical, Sweden). The RR-intervals were expressed as centiseconds with an accuracy of f 1 centisecond. The exported text files were fed into a custom-made software running under MS-Windows. Data was presented in segments of 500 beats each. The RR-intervals were checked for the occurrence of non-normal beats. The non-normal beats were deleted and interpolated using cubic spline interpolation. In addition, sudden long RR intervals, i.e. dropped beats or pauses, were interpolated. The periods of raw RR-data were corrected for linear trend using linear regression and subtraction of the mean of all RRintervals in the same segment.
Segments containing more than 4% non-normal beats were excluded. If more than 50% of the segments per time period (daytime, night-time or during 24 hours) had to be excluded for this reason the whole time period was withdrawn from analyses.
The time-domain measures; mean RR interval, standard deviation of the mean (SD-RR) and the variance of RR were determined for each segment. The SD of normal RR intervals (NN intervals) were calculated and defined as the mean of the SD of all segments of a 24-hour ECG recording, which is the SDNN index15.
In the frequency-domain analysis, the power at different frequencies was determined using an autoregressive spectral analysis method16. The model order of the autoregressive spectral analysis (number of coefficients in the polynomial describing the time series) was constantly set to 18. The following frequency domain indices were used: VLF, very-lowfrequency power, 0.0033-0.04 Hz; LF, low-frequency power, 0.04-o. 15 Hz; HF, high-frequency power, 0.15-0.40 Hz; TP, total-power, 0.0033-0.40 Hz; a ratio between the low-and high-frequency power, LF/HF. The physiological correlation to these indices is not fully understood. In a very simplified fashion LF is considered to mainly reflect sympathetic tone and HF is a marker for parasympathetic tone.
The segments were computed to a mean of three defined time periods according to previous suggestions", which were (1) a night period between midnight and 5 am, (2) a day period between 7.30 am and 9.30 pm and (3) a 24-hour period.
The study was approved by the Medical Ethics Committee of the Karolinska Institute and all subjects gave their informed consent.
Statistical methods
Data of the frequency domain components were log transformed, except the ratio of LF/HF, because their distribution was positively skewed. Data were fed into a Macintosh computer and processed in Microsoft Excel (4.0) and Statview SE + Graphics (1.02). Differences in conduction intervals and heart-rate variability variables between the last day on drug treatment and the following 4 days after drug withdrawal were tested using analysis of variance (ANOVA) for repeated measures. 
Plasma concentrations
The reduction in carbamazepine and phenytoin plasma levels after stopping drug treatment is shown in Fig. 1 .
Arrhythmia analyses
Patient 3 had a 2:1 atria1 flutter with a heart rate of 120 beats/minute, which was unaffected by the withdrawal of phenytoin. Five patients had changes in their arrhythmia profiles, shown by Fig. 2(a) and (b). Two patients (pts 4, 5) had a decrease in sinus pauses and in pt 10, the number of sinus pauses increased slightly from 550 episodes on day 1 to 683 episodes on day 5. In addition there was an increase of short runs of supraventricular tachycardias from 2 episodes on day 1 to 98 episodes on day 5, with a corresponding increase in posttachycardia pauses from 2 to 63 episodes. Patient 8 had a decreasing number of episodes of second-degree atrioventricular block with 2: 1 conduction (from 17 episodes on day 1 to 6 episodes on day 5). Three patients (pts 4.6, 10) had an increase in ventricular premature beats of > 10 times. but no ventricular tachycardia was recorded. 
Conduction intervals
Two patients (pts 2, 10) had intraventricular conduction defects, which were unaffected by withdrawal of the drugs. There was no statistically significant change in any variable analysed from day 1 to day 5.
Heart-rate variability
Nine patients were included in this analysis, while the patient with the atria1 flutter was excluded. Two patients (pts 4, 10) are represented with data up to the second and third day, respectively, since after that > 50% of the segments/day had to be excluded because of the increasing number of ventricular premature beats; see arrhythmia analysis. There was no statistically significant change in mean 24-hour heart rate from day 1 to day 5. In the time domain the SDNN index decreased (ANOVA repeated measures, P = 0.03), Fig. 3(a) .
There was also a significant reduction of heart-rate variability in the frequency domain. The results were similar for the 24-hour, daytime and night-time analyses. Therefore only the 24-hour results are presented in Fig. 3(b) showing a significant reduction of TP, VLF, and LF, but no significant changes for HF during the withdrawal period. The ratio of LF/HF expressed as a mean (fSEM) from days 1 and 5 were 2.29 (0.44) and 2.68 (0.44) respectively (ANOVA repeated measures were not significant). If the only remaining patient with phenytoin treatment was excluded from the analysis the changes of the eight carbamazepine-treated patients remained significant.
DISCUSSION
Discussions on mechanisms behind SUD in epilepsy have previously been focused on seizure-related events. We point at drug-related non-ictal possible mechanisms. Our intention in this investigation was to study the autonomic modulation, by means of heartrate variability analysis, and the arrhythmia profile during a drug situation similar to non-compliance which has been suggested to be associated with SUD.
Arrhythmias
Morganroth ef a1'8 defined the variability of ventricular premature beats in patients with a variety of cardiac-disease states and postulated that a more than IO-fold increase could be considered as a significant sign of a proarrhythmic development. Our study population is different, but there is no reason to assume a higher spontaneous variability in ventricular premature beats in these patients. A significant increase was thus observed in three of them.
The majority of our patients were included due to a suspicion of a drug-induced bradycardia, and based on previous experience' ', " any depressant effect on sinus node function and atrioventricular conduction would presumably be partially or completely reversible. As anticipated a reduction of sinus pauses was also documented in two patients as well as a reduction of the episodes of second-degree atrioventricular block in the only patient with this conduction defect, Fig. 2(b) .
Heart-rate variability A significant reduction of the SDNN index in the time domain and TP, VLF, and LF in the frequency domain was found after drug withdrawal. A change in this direction was previously shown to predict allcause mortality in post myocardial infarction populations . ","
Interestingly the reduction of VLF power was most strongly associated with arrhythmic death rather than with all-cause mortality or cardiac death2'. The SDNN index, Fig. 3 (a) in our study was lower on day 1 than values found in healthy individuals of similar age" and consequently, even lower at day 5. However, this time-domain index at day 5 was on the same level as in patients with ischaemic heart disease", but higher than in patients surviving a cardiac arrestZ2.
In five of our patients a previous 24-hour ECG registration had been performed on the same drug treatment and within the last 3 months. In these patients coefficient of variation was calculated for SDNN, TP, VLF, I-IF and LF/HF indices, and was found to be around 10%. Day-to-day variation of heart rate is low in different subsets of patients and even lower in those with a reduced heart-rate variability (reviewed in 23).
Mechanisms of sudden unexpected death in patients with epilepsy One interesting and unpredicted observation was the significant increase in ventricular premature beats in three patients, Fig. 2(a) . Two of them (pts 4. 6) had no myocardial disease and withdrawal of these drugs was therefore not expected to be accompanied by an increased ventricular automaticity, unless drug withdrawal produced a rebound phenomenon, which has not previously been reported with these or similar drugs.
Many authors have used repetitive ventricular premature beats as an electrophysiological marker when studying the effects of psychological stress on cardiac vulnerability (reviewed in 24). Such electrical instability could be due to many neurogenic factors, such as autonomic dysfunction, non-uniform peripheral neural discharges, interictal activity or ictal epileptic activity (reviewed in 25).
A more general observation in this study was the change in heart-rate variability. Normally this variability is the consequence of a complex interaction between peripheral and central nervous system activity .
26 Both drugs, however, have central as well as peripheral effects, although the design of our study does not allow any separation of the two.
When it comes to the SUD issue both peripheral and central nervous imbalance might be of importance in the development of ventricular arrhythmias. In animal studies instantaneous changes in both sympathetic and parasympathetic activity can induce fatal brady-or tachyarrhythmias (reviewed in 27, 5). A reduction in heart-rate variability is considered to be equivalent to an impaired autonomic nervous balance and has been documented to be a predictor for an increased risk of sudden death in patients with diabetic neuropathy, congestive heart failure and in post acute myocardial infarction'5* 1g,20*28-30. The occurrence of even minimal interictal epileptogenic activity can cause profound changes of centrally mediated autonomic activity and balance in animal studies (reviewed in 5). The QT interval is influenced by autonomic changes and a significant increase in the heartrate corrected QT interval has been demonstrated during epileptiform discharges in a group of patients, who later on suffered from SUD, compared to an agematched control group of patients with epilepsy3t. There were no changes between the daily assessment of the heart-rate-corrected QT interval in our study.
However, due to the access of only two leads we were not able to analyse any changes in regional differences (dispersion) of the JT/QT intervals, which might be more important for arrythmogenesis than the single-lead QT interva13'.
Limitations
A selected group of patients with allergic or cardiac side effects justifying abrupt withdrawal of carbamazepine or phenytoin was studied, and with an age range different from those patients with the highest risk for SUD in epilepsy. However, our group of patients did not have an expected increased risk for ventricular arrhythmias, Table 1 .
The results should, however, not automatically be extrapolated to the epilepsy population in general and need confirmation. Our observations, however, reflect the intricate interactions between the nervous system, the cardiovascular system and ion-channel active drugs used to suppress electrical excitability, and what might happen in relation to sudden withdrawal of sodium-channel-blocking antiepileptic drugs.
CONCLUSIONS
This study demonstrates that abrupt withdrawal of antiepileptic treatment reduced heart-rate variability suggesting an altered autonomic modulation, which in other patient populations has been associated with increased mortalityt5* 'g.20.22*2g*30. The withdrawal of these drugs induced an expected reduction in bradycardias in a subgroup of patients. However, there was also an unexpected IO-fold increase in ventricular premature beats in some patients suggesting increased electrical instability. Since reduced heart-rate variability signals a state of increased electrical vulnerability and ventricular premature beats might trigger life-threatening ventricular arrhythmias our observations point to two important factors that might contribute to an increased risk for sudden death during abrupt withdrawal of sodium-channel-blocking antiepileptic drugs even in the absence of seizures. 
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